Haskell Christopher A, Ribeiro Sofia, Horuk Richard
Department of Immunology, Berlex Biosciences, Richmond, CA 94804, USA.
Curr Opin Investig Drugs. 2002 Mar;3(3):399-405.
Recent studies in transplant biology have demonstrated a role for chemokines in the migration of leukocytes into transplanted tissue. There is further evidence that modulation of the action of chemokines at their receptors can improve the outcome of acute rejection as well as long-term graft survival. A number of clinical therapies, based on both small molecules and biologicals, are currently under investigation with the potential for selective immunosupression. This article discusses the chemokines and receptors identified as the best characterized molecular targets, as well as the therapies under investigation for these targets.
近期移植生物学研究表明，趋化因子在白细胞迁移至移植组织的过程中发挥作用。进一步的证据显示，调节趋化因子在其受体上的作用，可改善急性排斥反应的结果以及移植物的长期存活情况。目前，一些基于小分子和生物制剂的临床疗法正在研究中，具有选择性免疫抑制的潜力。本文讨论了已被确定为特征最明确的分子靶点的趋化因子和受体，以及针对这些靶点正在研究的疗法。
